Epigenetic regulation of microRNAs controlling CLDN14 expression as a mechanism for renal calcium handling

Journal of the American Society of Nephrology

Volumn 26, Issue 3, 2015, Pages 663-676

  Gong, Yongfeng ^a   Himmerkus, Nina ^b   Plain, Allein ^b   Bleich, Markus ^b   Hou, Jianghui ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Christian Albrechts University Kiel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; CLAUDIN 14; CREATININE; LOOP DIURETIC AGENT; MAGNESIUM ION; MEMBRANE PROTEIN; MICRORNA; MICRORNA 374; MICRORNA 9; UNCLASSIFIED DRUG; VORINOSTAT; CALCIUM; CLAUDIN; HISTONE DEACETYLASE INHIBITOR; MAGNESIUM; MIRN374 MICRORNA 374, HUMAN; MIRN92 MICRORNA, HUMAN; NAPHTHALENE DERIVATIVE;

ABNORMAL URINE COMPOSITION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT HYPOCALCEMIA; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPERCALCIURIA; HYPERMAGNESIURIA; HYPOCALCEMIA; HYPOCALCIURIA; IN VITRO STUDY; IN VIVO STUDY; ION CONDUCTANCE; KIDNEY PERFUSION; MAGNESIUM EXCRETION; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SINGLE DRUG DOSE; SYSTEMIC THERAPY; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HYPOPARATHYROIDISM; KIDNEY; KNOCKOUT MOUSE; METABOLISM; URINE;

ANIMALS; CALCIUM; CINACALCET HYDROCHLORIDE; CLAUDINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HYPERCALCIURIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; KIDNEY; MAGNESIUM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; NAPHTHALENES; RECEPTORS, CALCIUM-SENSING;

EID: 84924021629     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014020129     Document Type: Article

References (52)

1. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP: Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285: 103-106, 1999
2. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppner H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhauss SC, Nurnberg P, Weber S: Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79: 949-957, 2006
3. Greger R: Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron. Physiol Rev 65: 760-797, 1985
4. Hou J, Paul DL, Goodenough DA: Paracellin-1 and the modulation of ion selectivity of tight junctions. J Cell Sci 118: 5109-5118, 2005
5. Hou J, Renigunta A, Konrad M, Gomes AS, Schneeberger EE, Paul DL, Waldegger S, Goodenough DA: Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 118: 619-628, 2008
6. Hou J, Shan Q, Wang T, Gomes AS, Yan Q, Paul DL, Bleich M, Goodenough DA: Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 282: 17114-17122, 2007
7. Hou J, Renigunta A, Gomes AS, Hou M, Paul DL, Waldegger S, Goodenough DA: Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci U S A 106: 15350-15355, 2009
8. Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, Sulem P, Halldorsson BV, de Vegt F, d'Ancona FC, den Heijer M, Franzson L, Christiansen C, Alexandersen P, Rafnar T, Kristjansson K, Sigurdsson G, Kiemeney LA, Bodvarsson M, Indridason OS, Palsson R, Kong A, Thorsteinsdottir U, Stefansson K: Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41: 926-930, 2009
9. ++ transport in response to CaSR signalling via a novel microRNA pathway. EMBO J 31: 1999-2012, 2012
10. ++ metabolism via NFAT-microRNA-based mechanisms. J Am Soc Nephrol 25: 745-760, 2014
11. Hou J, Rajagopal M, Yu AS: Claudins and the kidney. Annu Rev Physiol 75: 479-501, 2013
12. Dimke H, Hoenderop JG, Bindels RJ: Molecular basis of epithelial Ca2+ and Mg2+ transport: Insights from the TRP channel family. J Physiol 589: 1535-1542, 2011
13. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993
14. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG: Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993
15. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG: Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 8: 303-307, 1994
16. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV: A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335: 1115-1122, 1996
17. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaître X, Paillard M, Planelles G, Déchaux M, Miller RT, Antignac C: Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13: 2259-2266, 2002
18. Kinoshita Y, Hori M, Taguchi M, Watanabe S, Fukumoto S: Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia. J Clin Endocrinol Metab 99: E363-E368, 2014
19. Johnstone RW: Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002
20. Helin K, Dhanak D: Chromatin proteins and modifications as drug targets. Nature 502: 480-488, 2013
21. Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, Helquist P, Wiest O, Maxfield FR: Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A 108: 5620-5625, 2011
22. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485, 2012
23. Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009
24. Coward WR, Watts K, Feghali-Bostwick CA, Jenkins G, Pang L: Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol 30: 2874-2886, 2010
25. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R: Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 13: 563-567, 2006
26. Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90, 2007
27. Ben-Yosef T, Belyantseva IA, Saunders TL, Hughes ED, Kawamoto K, Van Itallie CM, Beyer LA, Halsey K, Gardner DJ, Wilcox ER, Rasmussen J, Anderson JM, Dolan DF, Forge A, Raphael Y, Camper SA, Friedman TB: Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degeneration. Hum Mol Genet 12: 2049-2061, 2003
28. Ryan MP, Devane J, Ryan MF, Counihan TB: Effects of diuretics on the renal handling of magnesium. Drugs 28[Suppl 1]: 167-181, 1984
29. Ryan MP: Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med 82: 38-47, 1987
30. Breiderhoff T, Himmerkus N, Stuiver M, Mutig K, Will C, Meij IC, Bachmann S, Bleich M, Willnow TE, Müller D: Deletion of claudin-10 (Cldn10) in the thick ascending limb impairs paracellular sodium permeability and leads to hypermagnesemia and nephrocalcinosis. Proc Natl Acad Sci U S A 109: 14241-14246, 2012
31. Naro F, De Arcangelis V, Coletti D, Molinaro M, Zani B, Vassanelli S, Reggiani C, Teti A, Adamo S: Increase in cytosolic Ca2+ induced by elevation of extracellular Ca2+ in skeletal myogenic cells. Am J Physiol Cell Physiol 284: C969-C976, 2003
32. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M: Silencing of microRNAs in vivo with ' antagomirs'. Nature 438: 685-689, 2005
33. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon GJ, Kauppinen S: Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378, 2011
34. Elmén J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjärn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S: Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36: 1153-1162, 2008
35. Castoldi M, Vujic Spasic M, Altamura S, Elmén J, Lindow M, Kiss J, Stolte J, Sparla R, D'Alessandro LA, Klingmüller U, Fleming RE, Longerich T, Gröne HJ, Benes V, Kauppinen S, Hentze MW, Muckenthaler MU: The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 121: 1386-1396, 2011
36. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, Rossi JJ, Natarajan R: TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11: 881-889, 2009
37. Gebeshuber CA, Kornauth C, Dong L, Sierig R, Seibler J, Reiss M, Tauber S, Bilban M, Wang S, Kain R, Böhmig GA, Moeller MJ, Gröne HJ, Englert C, Martinez J, Kerjaschki D: Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med 19: 481-487, 2013
38. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010
39. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ: Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 115: 1651-1658, 2005
40. Wilcox ER, Burton QL, Naz S, Riazuddin S, Smith TN, Ploplis B, Belyantseva I, Ben-Yosef T, Liburd NA, Morell RJ, Kachar B, Wu DK, Griffith AJ, Riazuddin S, Friedman TB: Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness DFNB29. Cell 104: 165-172, 2001
41. Van Lint C, Emiliani S, Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253, 1996
42. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000
43. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 19: 4999-5005, 1999
44. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9[10 Pt 1]: 3578-3588, 2003
45. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39, 2007
46. Fraczek J, Vanhaecke T, Rogiers V: Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 9: 441-457, 2013
47. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M: Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12: 3997-4003, 2006
48. Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P: Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 26: 483-488, 2008
49. Riccardi D, Brown EM: Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 298: F485-F499, 2010
50. Bhakat KK, Izumi T, Yang SH, Hazra TK, Mitra S: Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. EMBO J 22: 6299-6309, 2003
51. Himmerkus N, Shan Q, Goerke B, Hou J, Goodenough DA, Bleich M: Salt and acid-base metabolism in claudin-16 knockdown mice: Impact for the pathophysiology of FHHNC patients. Am J Physiol Renal Physiol 295: F1641-F1647, 2008
52. Greger R: Cation selectivity of the isolated perfused cortical thick ascending limb of Henle's loop of rabbit kidney. Pflugers Arch 390: 30-37, 1981